Trial Profile
Phase II study of gemcitabine and S-1 combination therapy in advanced pancreatic cancer with malignant ascites.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2013
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenosquamous carcinoma; Malignant ascites; Pancreatic cancer
- Focus Therapeutic Use
- 01 Oct 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 20 Jul 2012 New trial record